Sept 18 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES EARLY POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF LEAD CANDIDATE DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA® IN PATIENTS WITH DLBCL.IMV INC - DATA SHOWED TWO OF FIRST FOUR EVALUABLE PARTICIPANTS SHOWED TUMOR REGRESSIONS AT FIRST ON-TREATMENT CT SCAN.IMV INC - IN TRIAL, COMBINATION THERAPY APPEARS TO DEMONSTRATE AN ACCEPTABLE SAFETY PROFILE, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE.IMV INC - FIRST ENROLLED PARTICIPANT DEMONSTRATED A TUMOR REGRESSION OF 48% AT FIRST ON-TREATMENT SCAN.IMV INC - SECOND PARTICIPANT DEMONSTRATED A PARTIAL RESPONSE (PR) VIA A TUMOR REGRESSION OF 66% AT FIRST ON-TREATMENT SCAN.IMV INC - PRELIMINARY DATA FROM THIRD PARTICIPANT IN TRIAL OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA DEMONSTRATED STABLE DISEASE.IMV INC - FOURTH PARTICIPANT HAD EARLY DISEASE PROGRESSION LESS THAN TWO MONTHS FOLLOWING TREATMENT INITIATION AND WAS DISCONTINUED FROM STUDY.
Full Article
May 31 (Reuters) - Imv Inc ::IMV INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.
Full Article
Jan 25 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES $12.5 MILLION BOUGHT DEAL OFFERING.IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE.
Full Article
Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVACDEMONSTRATE TOLERABLE SAFETY PROFILE.
Full Article
Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share $0.02.
Full Article
Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.
Full Article
Aug 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces financial results for quarter ended June 30, 2017.Q2 basic loss per share c$0.02.
Full Article
July 12 (Reuters) - Immunovaccine Inc :Immunovaccine achieves breakthrough in support of developing personalized cancer immunotherapies.Immunovaccine Inc - filed a patent application covering the novel DepoVax-based rapid formulation process.
Full Article
May 31 (Reuters) - Immunovaccine Inc ::Immunovaccine announces $10 million bought deal offering.Immunovaccine Inc says intends to use net proceeds of offering to advance company's various depovax™-based products clinical studies.Immunovaccine Inc - entered into a bought deal financing agreement to sell 7.7 million common shares of corporation at a price of $1.30 per common share.Immunovaccine Inc - offering is expected to close on or about June 21, 2017.
Full Article
May 16 (Reuters) - Immunovaccine Inc :Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug.Immunovaccine Inc says expects trial to begin enrolling patients following receipt of regulatory clearance from Health Canada.
Full Article
Earnings vs. 
Estimates